Survivorship Considerations After CAR T-Cell Therapy

Elisa Becze BA, ELS, Editor
Voice

Description

As more patients receive treatment with chimeric antigen receptor (CAR) T-cell therapy, oncology nurses will need to be aware of the long-term effects of treatment that may persist into survivorship. However, because the treatment is so new, studies measuring those patient-reported concerns are still forthcoming. The majority of today’s recommendations for survivorship management are based on experts’ clinical experience.

View Article @ voice.ons.org

ONS Voice Articles

ONS's member magazine articles.

View All Voice Articles